KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Operations: 2009-2024

Historic Cash from Operations for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $157.7 million.

  • Acadia Pharmaceuticals' Cash from Operations rose 17.46% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year decrease of 1.86%. This contributed to the annual value of $157.7 million for FY2024, which is 844.31% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Cash from Operations stood at $157.7 million for FY2024, which was up 844.31% from $16.7 million recorded in FY2023.
  • Acadia Pharmaceuticals' Cash from Operations' 5-year high stood at $157.7 million during FY2024, with a 5-year trough of -$136.2 million in FY2020.
  • For the 3-year period, Acadia Pharmaceuticals' Cash from Operations averaged around $20.1 million, with its median value being $16.7 million (2023).
  • Data for Acadia Pharmaceuticals' Cash from Operations shows a peak YoY skyrocketed of 844.31% (in 2024) over the last 5 years.
  • Acadia Pharmaceuticals' Cash from Operations (Yearly) stood at -$136.2 million in 2020, then climbed by 7.72% to -$125.7 million in 2021, then rose by 9.25% to -$114.0 million in 2022, then soared by 114.65% to $16.7 million in 2023, then spiked by 844.31% to $157.7 million in 2024.